JP2020172505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020172505A5 JP2020172505A5 JP2020113725A JP2020113725A JP2020172505A5 JP 2020172505 A5 JP2020172505 A5 JP 2020172505A5 JP 2020113725 A JP2020113725 A JP 2020113725A JP 2020113725 A JP2020113725 A JP 2020113725A JP 2020172505 A5 JP2020172505 A5 JP 2020172505A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- compound according
- amino acid
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 239000013598 vector Substances 0.000 claims 3
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 102100031506 Complement C5 Human genes 0.000 claims 1
- 108010028773 Complement C5 Proteins 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1350986 | 2013-08-28 | ||
| SE1350986-4 | 2013-08-28 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537298A Division JP6767865B2 (ja) | 2013-08-28 | 2014-08-28 | ヒト補体ｃ５に結合する安定なポリペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020172505A JP2020172505A (ja) | 2020-10-22 |
| JP2020172505A5 true JP2020172505A5 (enExample) | 2020-12-03 |
Family
ID=51539238
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537298A Active JP6767865B2 (ja) | 2013-08-28 | 2014-08-28 | ヒト補体ｃ５に結合する安定なポリペプチド |
| JP2020113725A Pending JP2020172505A (ja) | 2013-08-28 | 2020-07-01 | ヒト補体ｃ５に結合する安定なポリペプチド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537298A Active JP6767865B2 (ja) | 2013-08-28 | 2014-08-28 | ヒト補体ｃ５に結合する安定なポリペプチド |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9994626B2 (enExample) |
| EP (2) | EP3038633B1 (enExample) |
| JP (2) | JP6767865B2 (enExample) |
| KR (1) | KR102446636B1 (enExample) |
| CN (1) | CN105658228B (enExample) |
| AU (1) | AU2014314222B2 (enExample) |
| BR (1) | BR112016003142A2 (enExample) |
| CA (1) | CA2926976C (enExample) |
| CY (1) | CY1123732T1 (enExample) |
| DK (1) | DK3038633T3 (enExample) |
| ES (1) | ES2842105T3 (enExample) |
| HR (1) | HRP20210013T1 (enExample) |
| HU (1) | HUE052613T2 (enExample) |
| IL (1) | IL244218A (enExample) |
| LT (1) | LT3038633T (enExample) |
| MX (1) | MX382140B (enExample) |
| MY (1) | MY173804A (enExample) |
| NZ (1) | NZ718153A (enExample) |
| PH (1) | PH12016500371A1 (enExample) |
| PL (1) | PL3038633T3 (enExample) |
| PT (1) | PT3038633T (enExample) |
| RS (1) | RS61347B1 (enExample) |
| RU (2) | RU2733897C2 (enExample) |
| SA (1) | SA516370622B1 (enExample) |
| SG (1) | SG11201602679VA (enExample) |
| SI (1) | SI3038633T1 (enExample) |
| SM (1) | SMT202100006T1 (enExample) |
| UA (1) | UA117933C2 (enExample) |
| WO (1) | WO2015028558A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3511339B1 (en) | 2012-02-20 | 2025-04-09 | IPC Research, LLC | Polypeptides binding to human complement c5 |
| AU2014314214C1 (en) * | 2013-08-28 | 2019-01-24 | Affibody Ab | Binding polypeptides having a mutated scaffold |
| JP6767865B2 (ja) * | 2013-08-28 | 2020-10-14 | スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） | ヒト補体ｃ５に結合する安定なポリペプチド |
| UY37651A (es) * | 2017-03-31 | 2018-10-31 | Swedish Orphan Biovitrum Ab Publ | Polipéptido de unión al il-1r-i |
| IL307197B1 (en) | 2017-07-11 | 2025-11-01 | Alexion Pharma Inc | Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof |
| WO2022171892A1 (en) * | 2021-02-15 | 2022-08-18 | Affibody Ab | New her2-binding polypeptide |
| CN118804764A (zh) * | 2021-11-01 | 2024-10-18 | Ipc研究有限责任公司 | C5结合蛋白的施用 |
| WO2024227886A1 (en) | 2023-05-02 | 2024-11-07 | Mebrahtu Aman | Bispecific binding molecule |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US6534058B2 (en) | 2000-10-10 | 2003-03-18 | Tanox, Inc. | Anti-C5 monoclonal antibodies |
| AT410798B (de) * | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| ES2283594T5 (es) | 2001-08-17 | 2016-03-15 | Genentech, Inc. | Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US7348401B2 (en) * | 2003-09-10 | 2008-03-25 | Innate Biotech, Inc. | Peptides that inhibit complement activation |
| SE0400274D0 (sv) * | 2004-02-09 | 2004-02-09 | Affibody Ab | New polypeptide |
| GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| CA3009846C (en) * | 2006-03-08 | 2021-08-31 | David Epstein | Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders |
| SI2359834T1 (sl) | 2006-03-15 | 2017-02-28 | Alexion Pharmaceuticals, Inc. | Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa |
| AU2008281913B2 (en) | 2007-07-31 | 2013-11-07 | Affibody Ab | New albumin binding compositions, methods and uses |
| ES2373832T3 (es) * | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| US9187535B2 (en) | 2007-12-19 | 2015-11-17 | Affibody Ab | Polypeptide derived from protein A and able to bind PDGF |
| EP2072525A1 (en) | 2007-12-21 | 2009-06-24 | Affibody AB | New polypeptides having affinity for HER2 |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| WO2012004384A2 (en) * | 2010-07-09 | 2012-01-12 | Affibody Ab | Polypeptides |
| EP3511339B1 (en) * | 2012-02-20 | 2025-04-09 | IPC Research, LLC | Polypeptides binding to human complement c5 |
| JP5980104B2 (ja) | 2012-11-22 | 2016-08-31 | 三菱電機株式会社 | 液晶表示装置の製造方法および液晶表示装置の製造システム |
| WO2014096163A1 (en) | 2012-12-19 | 2014-06-26 | Affibody Ab | New polypeptides |
| AU2014314214C1 (en) * | 2013-08-28 | 2019-01-24 | Affibody Ab | Binding polypeptides having a mutated scaffold |
| JP6767865B2 (ja) * | 2013-08-28 | 2020-10-14 | スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） | ヒト補体ｃ５に結合する安定なポリペプチド |
-
2014
- 2014-08-28 JP JP2016537298A patent/JP6767865B2/ja active Active
- 2014-08-28 MY MYPI2016700583A patent/MY173804A/en unknown
- 2014-08-28 HU HUE14765883A patent/HUE052613T2/hu unknown
- 2014-08-28 RU RU2016111115A patent/RU2733897C2/ru active
- 2014-08-28 BR BR112016003142A patent/BR112016003142A2/pt not_active Application Discontinuation
- 2014-08-28 CA CA2926976A patent/CA2926976C/en active Active
- 2014-08-28 MX MX2016002397A patent/MX382140B/es unknown
- 2014-08-28 NZ NZ718153A patent/NZ718153A/en unknown
- 2014-08-28 ES ES14765883T patent/ES2842105T3/es active Active
- 2014-08-28 RS RS20210005A patent/RS61347B1/sr unknown
- 2014-08-28 LT LTEP14765883.5T patent/LT3038633T/lt unknown
- 2014-08-28 PT PT147658835T patent/PT3038633T/pt unknown
- 2014-08-28 EP EP14765883.5A patent/EP3038633B1/en active Active
- 2014-08-28 PL PL14765883T patent/PL3038633T3/pl unknown
- 2014-08-28 RU RU2020128977A patent/RU2020128977A/ru unknown
- 2014-08-28 US US14/914,290 patent/US9994626B2/en active Active
- 2014-08-28 AU AU2014314222A patent/AU2014314222B2/en active Active
- 2014-08-28 CN CN201480057470.XA patent/CN105658228B/zh active Active
- 2014-08-28 SG SG11201602679VA patent/SG11201602679VA/en unknown
- 2014-08-28 KR KR1020167007498A patent/KR102446636B1/ko active Active
- 2014-08-28 DK DK14765883.5T patent/DK3038633T3/da active
- 2014-08-28 HR HRP20210013TT patent/HRP20210013T1/hr unknown
- 2014-08-28 WO PCT/EP2014/068282 patent/WO2015028558A1/en not_active Ceased
- 2014-08-28 SM SM20210006T patent/SMT202100006T1/it unknown
- 2014-08-28 EP EP20201264.7A patent/EP3811961B1/en active Active
- 2014-08-28 SI SI201431739T patent/SI3038633T1/sl unknown
- 2014-08-28 UA UAA201603124A patent/UA117933C2/uk unknown
-
2016
- 2016-02-22 IL IL244218A patent/IL244218A/en active IP Right Grant
- 2016-02-24 PH PH12016500371A patent/PH12016500371A1/en unknown
- 2016-02-25 SA SA516370622A patent/SA516370622B1/ar unknown
-
2020
- 2020-07-01 JP JP2020113725A patent/JP2020172505A/ja active Pending
- 2020-12-30 CY CY20201101229T patent/CY1123732T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020172505A5 (enExample) | ||
| CA2741302C (en) | Mapkap kinase inhibitor polypeptide for treating or preventing adhesions | |
| JP2010534486A5 (enExample) | ||
| RU2014137303A (ru) | Полипептиды, связывающиеся с компонентом с5 системы комплемента человека | |
| JP2018537087A5 (enExample) | ||
| JP2017521074A5 (enExample) | ||
| JP2015508652A5 (enExample) | ||
| RU2016111115A (ru) | Стабильные полипептиды, связывающиеся с с5 комплемента человека | |
| CN103459419B (zh) | 具有抗炎活性的基于人乳铁蛋白的肽 | |
| JP2018537089A5 (enExample) | ||
| JP2020518249A5 (enExample) | ||
| JP2017527558A5 (enExample) | ||
| US9060977B2 (en) | Heparin binding epidermal growth factor (HB-EGF) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation | |
| JP2024133479A5 (enExample) | ||
| WO2021198395A1 (en) | Surfactant protein d for use in treating coronavirus infections | |
| JP2004537284A5 (enExample) | ||
| JP2015525237A5 (enExample) | ||
| TW202237634A (zh) | 用於治療ｃｏｖｉｄ－１９之ｄｓｇ２組成物和方法 | |
| JP6532141B2 (ja) | 肝細胞増殖因子及びストローマ細胞由来因子１αを用いた末梢動脈疾患の予防または治療用組成物 | |
| JP2009507474A5 (enExample) | ||
| JP2008502323A5 (enExample) | ||
| JP2019525764A5 (enExample) | ||
| JP2002539829A5 (enExample) | ||
| JP2001072607A (ja) | 新規血管内皮機能改善法 | |
| KR101084529B1 (ko) | 인터루킨-24 또는 그를 암호화하는 유전자를 포함하는 고혈압 예방 또는 치료용 의약조성물 |